Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new GMP manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. These platforms are designed to advance cell therapies and accelerate progress in immuno-oncology and regenerative medicine.
Building on the success of the Echo™-NK platform for natural killer (NK) cells, the expanded Echo™ portfolio leverages Cellistic’s GMP expertise and its EMA-certified, FDA- and PMDA-compliant facility. The platforms enable scalable solutions across additional immune and regenerative cell types, addressing critical limitations in manufacturability and scalability that impact patient access and program viability.
Gustavo Mahler, CEO of Cellistic, said:
The 2025 launch of Echo™-NK marked a significant advancement in cell therapy manufacturing. Building on that foundation, our team has developed three platforms designed to overcome limitations in current approaches. These off-the-shelf allogeneic cell therapies provide a cost-effective way to ensure more patients can access life-changing treatments.
Each platform supports distinct therapeutic modalities:
-
Echo™-T – Produces iPSC-derived αβ T cells or Tregs with defined phenotype and predictable immune function, enabling reproducible development of immuno-oncology therapies.
-
Echo™-Cardio – Delivers iPSC-derived cardiomyocytes with homogeneous phenotype and functional relevance, supporting reliable cardiac regenerative programs.
-
Echo™-Endothelial – Provides iPSC-derived endothelial cells with consistent identity and function for therapies targeting vascular biology, inflammation, and the tumor microenvironment.
Mahler added:
Cellistic was created to make iPSC-based cell therapies mainstream. The addition of these platforms demonstrates that our technologies and expertise are ready to supply the next generation of cell therapies.
The new platforms complement the Cellistic Pulse™ and Echo™ portfolios, offering developers a turnkey path from gene-edited iPSCs to fully characterized, GMP-compliant cell therapy products. They are already supporting multiple active development programs, including those approaching IND submission.